January 2026: The TGA approved the importation of an alternative to Pramipexole Dihydrochloride Tablets 0.125mg, Pramipexole Dihydrochloride Tablets 0.25mg, Pramipexole Dihydrochloride Tablets 1mg  products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 30 April 2026 for 1 mg and 30 May 2026 for 0.125 mg and 0.250 mg tablets (unless lapsed on an earlier date). Contact Us for more details.

​

January 2026: The TGA approved the importation of an alternative to teriparatide 0.25 mg/mL (250mcg/mL) solution for injection products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 30 April 2026 (unless lapsed on an earlier date). Contact Us for more details.

​

January 2026: The TGA approved the importation of an alternative to Topotecan injection 4mg/4mL intravenous infusion products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 31 March 2026 (unless lapsed on an earlier date). Contact Us for more details.

​

November 2025: We’re excited to announce that our company has been recognized on The Australian Financial Review Fast 100 list for 2025. This achievement reflects our commitment to innovation, growth, and excellence. Thank you to our incredible team, partners and customers who made this possible!

​

November 2025: The TGA approved the importation of an alternative to teriparatide 0.25 mg/mL (250mcg/mL) solution for injection products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 31 January 2026 (unless lapsed on an earlier date). Contact Us for more details.

​

November 2025: The TGA approved the importation of an alternative to Topotecan injection 4mg/4mL intravenous infusion products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 31 January 2026 (unless lapsed on an earlier date). Contact Us for more details.​

​

October 2025: The TGA approved the importation of an alternative to Pramipexole Dihydrochloride Tablets 0.125mg, Pramipexole Dihydrochloride Tablets 0.25mg, Pramipexole Dihydrochloride Tablets 1mg  products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until January 2026 and March 2026  (unless lapsed on an earlier date). Contact Us for more details.

 

September 2025: The TGA approved the importation of an alternative to Topotecan injection 4mg/4mL intravenous infusion products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 30 November 2025 (unless lapsed on an earlier date). Contact Us for more details.

​

September 2025: The TGA approved the importation of an alternative to teriparatide 0.25 mg/mL (250mcg/mL) solution for injection products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until 30 November 2025 (unless lapsed on an earlier date). Contact Us for more details.

​

​​